(Q34726138)

4 August 2017

1 reference

title

Resource management in prevention of coronary heart disease: optimising prescription of lipid-lowering drugs (English)

1 reference

4 August 2017

1 reference

coronary artery disease

1 reference

James Shepherd

1

1 reference

PubMed ID

12103306

4 August 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

4 August 2017

1 reference

4 August 2017

359

1 reference

4 August 2017

2271-2273

1 reference

4 August 2017

9325

1 reference

Primary prevention of coronary heart disease: integrating risk assessment with intervention

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909299-1

7 January 2021

At what level of coronary heart disease risk should a statin be prescribed?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909299-1

7 January 2021

Debate: at what level of coronary heart disease risk should a statin be prescribed?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909299-1

7 January 2021

Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909299-1

7 January 2021

Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909299-1

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909299-1

7 January 2021

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909299-1

7 January 2021

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909299-1

7 January 2021

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909299-1

7 January 2021

MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2802%2909299-1

7 January 2021

10.1016/S0140-6736(02)09299-1

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12103306